Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Samir Parekh

Samir Parekh

MBBS
Icahn School of Medicine at Mount Sinai
Earlier use of cilta-cel is associated with better immune fitness in multiple myeloma: CARTITUDE-4 4:50
Earlier use of cilta-cel is associated with better immune fitness in multiple myeloma: CARTITUDE-4
Samir Parekh • 6 Dec 2025
Making CAR T-cell therapy for multiple myeloma available globally: what needs to be done? 0:59
Making CAR T-cell therapy for multiple myeloma available globally: what needs to be done?
Samir Parekh • 6 Dec 2025
The role of the immune system as a mechanism of resistance to T-cell engagers in multiple myeloma 5:15
The role of the immune system as a mechanism of resistance to T-cell engagers in multiple myeloma
Samir Parekh • 19 Sep 2025
The potential of iberdomide to enhance CAR T-cell expansion and functionality in multiple myeloma 1:13
The potential of iberdomide to enhance CAR T-cell expansion and functionality in multiple myeloma
Samir Parekh • 19 Sep 2025
Improving CAR-T functionality with CELMoDs in multiple myeloma 1:13
Improving CAR-T functionality with CELMoDs in multiple myeloma
Samir Parekh • 31 Jan 2025
Understanding inherited contributions to myeloma risk to improve risk stratification and treatment 1:37
Understanding inherited contributions to myeloma risk to improve risk stratification and treatment
Samir Parekh • 31 Jan 2025
Novel biomarkers of response to immunotherapies in multiple myeloma 1:19
Novel biomarkers of response to immunotherapies in multiple myeloma
Samir Parekh • 31 Jan 2025
Regression of smoldering myeloma with Gaucher disease treatment 2:55
Regression of smoldering myeloma with Gaucher disease treatment
Samir Parekh • 2 Jun 2024
The discovery of pathogenic germline variants in patients with myeloma 2:55
The discovery of pathogenic germline variants in patients with myeloma
Samir Parekh • 2 Jun 2024
Sequencing immunotherapies in multiple myeloma 3:11
Sequencing immunotherapies in multiple myeloma
Samir Parekh • 2 Jun 2024
Looking forward to ASH 2021: key updates in multiple myeloma 1:03
Looking forward to ASH 2021: key updates in multiple myeloma
Samir Parekh • 10 Nov 2021
COVID-19 prophylaxis: bolstering boosters 2:42
COVID-19 prophylaxis: bolstering boosters
Samir Parekh • 10 Nov 2021
How does myeloma treatment choice impact COVID-19 vaccination response? 9:04
How does myeloma treatment choice impact COVID-19 vaccination response?
Samir Parekh • 10 Nov 2021
Refining the current staging system for multiple myeloma 2:32
Refining the current staging system for multiple myeloma
Samir Parekh • 10 Nov 2021
The content of VJHemOnc is intended for healthcare professionals